Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Not Applicable

Completed

• Conditions: Metastatic Castration Resistant Prostate Cancer Patients

• Registration Number: NCT01786031
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2012-12-03
• Study First Submitted QC: 2013-02-06
• Study First Posted: 2013-02-07
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-05
• Last Update Posted: 2016-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 55

Inclusion Criteria

• Prostate Cancer patients
• Castration Resistant
• Prostatic tissue available
• Metastasis which may be biopsied

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Biomarker	assessed at the end of recruitment, up to 2 years	success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC

Trial Locations

Locations (1)

Institut Gustave Roussy; 🇫🇷 Villejuif, Val de Marne, France